» Articles » PMID: 26838022

Linguistic Validation of the Spanish Version of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Overview
Specialties Critical Care
Oncology
Date 2016 Feb 4
PMID 26838022
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The U.S. NCI's PRO-CTCAE is a library of self-report items for assessing symptomatic adverse events in cancer clinical trials from the patient perspective. The aim of this study was to translate and linguistically validate a Spanish version.

Methods: PRO-CTCAE's 124 items were translated from English into Spanish using multiple forward and back translations. Native Spanish speakers undergoing cancer treatment were enrolled at six cancer treatment sites. Participants each completed approximately 50 items and were then interviewed using cognitive probes. The interviews were analyzed at the item level by linguistic themes, and responses were examined for evidence of equivalence to English. Items for which ≥20 % of participants experienced difficulties were reviewed, and phrasing was revised and then retested in subsequent interviews. Items where <20 % of respondents experienced difficulties were also reviewed and were considered for rephrasing and retesting.

Results: One hundred nine participants from diverse Spanish-speaking countries were enrolled (77 in Round 1 and 32 in Round 2). A majority of items were well comprehended in Round 1. Two items presented difficulties in ≥20 % of participants and were revised/retested without further difficulties. Two items presented difficulties in <20 %, and when retested exhibited no further difficulties. Two items presented difficulties in <20 %, but were not revised due to lack of alternatives. Sixteen items presented difficulties in ≤12 % and were not revised because difficulties were minor.

Conclusions: The Spanish PRO-CTCAE has been developed and refined for use in Spanish-speaking populations, with high levels of comprehension and equivalence to the English PRO-CTCAE.

Trial Registration: ClinicalTrials.gov:NCT01436240.

Citing Articles

Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol.

Martinez F, Taramasco C, Espinoza M, Acevedo J, Goic C, Nervi B Diagnostics (Basel). 2024; 14(6).

PMID: 38535039 PMC: 10968981. DOI: 10.3390/diagnostics14060619.


Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Schroeder K, Rizzieri T, Lion R, Mtenga N, Gisiri M, McFatrich M J Patient Rep Outcomes. 2023; 7(1):56.

PMID: 37306774 PMC: 10260717. DOI: 10.1186/s41687-023-00598-4.


Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials.

Roth M, Parsons S, Ganz P, Wagner L, Hinds P, Alexander S J Natl Cancer Inst. 2022; 115(1):21-28.

PMID: 36266760 PMC: 9830479. DOI: 10.1093/jnci/djac166.


An interactive mobile application versus an educational booklet to promote job retention in women undergoing adjuvant chemotherapy for breast cancer: a randomized controlled trial.

Blinder V, Patil S, Finik J, Makower D, Muppidi M, Lichtenthal W Trials. 2022; 23(1):840.

PMID: 36192754 PMC: 9527379. DOI: 10.1186/s13063-022-06580-7.


Perceived Severity of COVID-19 in a Longitudinal Study in Detroit, Michigan.

Yang D, Wagner A, Gorin S Ethn Dis. 2022; 32(3):231-238.

PMID: 35909636 PMC: 9311308. DOI: 10.18865/ed.32.3.231.


References
1.
Wilson M, Collyar D, Chingos D, Friedlander M, Ho T, Karakasis K . Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol. 2015; 16(1):e43-52. DOI: 10.1016/S1470-2045(14)70380-8. View

2.
Basch E, Reeve B, Mitchell S, Clauser S, Minasian L, Sit L . Electronic toxicity monitoring and patient-reported outcomes. Cancer J. 2011; 17(4):231-4. PMC: 3855320. DOI: 10.1097/PPO.0b013e31822c28b3. View

3.
Hay J, Atkinson T, Reeve B, Mitchell S, Mendoza T, Willis G . Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res. 2013; 23(1):257-69. PMC: 3896507. DOI: 10.1007/s11136-013-0470-1. View

4.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A . Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005; 8(2):94-104. DOI: 10.1111/j.1524-4733.2005.04054.x. View

5.
Basch E, Abernethy A, Daniel Mullins C, Reeve B, Smith M, Coons S . Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012; 30(34):4249-55. DOI: 10.1200/JCO.2012.42.5967. View